159 related articles for article (PubMed ID: 23936794)
1. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma.
Alexandrakis MG; Roussou P; Pappa CA; Messaritakis I; Xekalou A; Goulidaki N; Boula A; Tsirakis G
Biomed Res Int; 2013; 2013():389579. PubMed ID: 23936794
[TBL] [Abstract][Full Text] [Related]
2. Significance of Some Proliferation Markers and Some Prognostic Factors in Patients with Multiple Myeloma and their Impact on the Patients' Survival.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(5):2389-94. PubMed ID: 27268602
[TBL] [Abstract][Full Text] [Related]
3. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG
Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368
[TBL] [Abstract][Full Text] [Related]
4. Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity.
Kokonozaki M; Kanellou P; Pappa CA; Vyzoukaki R; Sarantoulaki S; Stavroulaki E; Kyriakaki S; Alegakis A; Boula A; Alexandrakis MG
Crit Rev Oncog; 2017; 22(3-4):255-262. PubMed ID: 29604902
[TBL] [Abstract][Full Text] [Related]
5. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.
Fragioudaki M; Tsirakis G; Pappa CA; Aristeidou I; Tsioutis C; Alegakis A; Kyriakou DS; Stathopoulos EN; Alexandrakis MG
Leuk Res; 2012 Aug; 36(8):1004-8. PubMed ID: 22498341
[TBL] [Abstract][Full Text] [Related]
6. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.
Bolkun L; Lemancewicz D; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
Ann Hematol; 2014 Apr; 93(4):635-44. PubMed ID: 24141333
[TBL] [Abstract][Full Text] [Related]
7. Cytokine profile in multiple myeloma.
Jasrotia S; Gupta R; Sharma A; Halder A; Kumar L
Cytokine; 2020 Dec; 136():155271. PubMed ID: 32916474
[TBL] [Abstract][Full Text] [Related]
8. B cell-activating factor: its clinical significance in multiple myeloma patients.
Fragioudaki M; Boula A; Tsirakis G; Psarakis F; Spanoudakis M; Papadakis IS; Pappa CA; Alexandrakis MG
Ann Hematol; 2012 Sep; 91(9):1413-8. PubMed ID: 22526370
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
10. Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(3):1351-5. PubMed ID: 27039771
[TBL] [Abstract][Full Text] [Related]
11. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
12. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
Hengeveld PJ; Kersten MJ
Blood Cancer J; 2015 Feb; 5(2):e282. PubMed ID: 25723853
[TBL] [Abstract][Full Text] [Related]
13. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.
Lemancewicz D; Bolkun L; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
Leuk Res; 2013 Sep; 37(9):1089-93. PubMed ID: 23768867
[TBL] [Abstract][Full Text] [Related]
15. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
16. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
17. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
18. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
19. [BAFF level in bone marrow and expression of BAFF receptor on B cells in multiple myeloma patients].
Zhou ZH; Zhang L; Pan QY; Huang BH; Zheng D; Liu JR; Li J; Luo SK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1131-4. PubMed ID: 23114133
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
